c-Jun N-terminal kinase-dependent mechanisms in respiratory disease

European Respiratory Journal

Volumn 28, Issue 3, 2006, Pages 651-661

  Bennett, B L ^a  

^a Celgene ^*  (United States)

Author keywords

C Jun N terminal kinase; Inflammation; Kinases; Pharmacotherapy; Signal transduction

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTISENSE OLIGONUCLEOTIDE; AS 602801; CC 401; CORTICOSTEROID; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 13; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; RANTES; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; APOPTOSIS; ARTICLE; ASTHMA; CELL TYPE; CLINICAL EXAMINATION; DISEASE COURSE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; INFLAMMATORY CELL; LUNG FIBROSIS; MEDIATOR; NONHUMAN; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT DISEASE; STIMULUS RESPONSE; SYMPTOM;

APOPTOSIS; CELL PROLIFERATION; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RESPIRATION DISORDERS;

EID: 33751297489     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00012106     Document Type: Article

References (97)

1. Ferguson S, Fasano S, Yang P, Brambilla R, Robinson T. Knockout of ERK1 enhances cocaine-evoked immediate early gene expression and behavioral plasticity. Neuropsychopharmacology 2006; Epub ahead of print PMID: 16407894.
2. Hatano N, Mori Y, Oh-hora M, et al. Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells 2003; 8: 847-856.
3. Sohn S, Sarvis B, Cado D, Winoto A. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 2002; 277: 43344-43351.
4. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-336.
5. Dong C, Yang D, Wysk M, Whitmarsh A, Davis R, Flavell R. Defective T cell differentiation in the absence of Jnk1. Science 1998; 282: 2092-2095.
6. David J-P, Sabapathy K, Hoffman O, Idarraga M, Wagner E. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002; 115: 4317-4325.
7. Yang D, Whitmarsh A, Conze D, et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998; 9: 575-585.
8. 2-terminal kinase-2-deficient mice. Cancer Res 2001; 61: 3908-3912.
9. Sabapathy K, Hu Y, Kallunki T, et al. JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. Curr Biol 1999; 9: 116-125.
10. Han Z, Chang L, Yamanishi Y, Karin M, Firestein G. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 2002; 46: 818-823.
11. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-874.
12. Yang D, Kuan C, Whitmarsh A, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 1997; 389: 865-870.
13. Allen M, Svensson S, Roach M, Hambor J, McNeish J, Gabel C. Deficiency of the stress kinase p38α results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme-deficient embryonic stem cells. J Exp Med 2000; 191: 859-870.
14. Beardmore V, Hinton H, Eftychi C, et al. Generation and characterization of p3813 (MAPK11) gene-targeted mice. Mol Cell Biol 2005; 25: 10454-10464.
15. Kuida K, Boucher D. Functions of MAP kinases: insights from gene-targeting studies. J Bioch (Tokyo) 2004; 135: 653-656.
16. Wallace E, Lyssikatos J, Yeh T, Winkler J, Koch K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 2005; 5: 215-229.
17. Brancho D, Tanaka N, Jaeschke A, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev 2003; 17: 1969-1978.
18. Han J, Jiang Y, Li Z, Kravchenko V, Ulevitch R. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997; 386: 296-299.
19. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat Cell Biol 1999; 1: 94-97.
20. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686.
21. Underwood D, Osborn R, Kotzer C, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000; 293: 281-288.
22. Underwood D, Osborn R, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol 2000; 279: L895-L902.
23. Lee M, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38α protein. Curr Med Chem 2005; 12: 2979-2994.
24. Davis R. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
25. Murray BW, Bennett BL, Sasaki D. Analysis of pharmacologic inhibitors of c-Jun N-terminal kinase. Methods Enzymol 2001; 332: 432-452.
26. Wakatsuki T, Schlessinger J, Elson E. The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci 2004; 29: 609-617.
27. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-E136.
28. Whitmarsh AJ, Cavanagh J, Tournier C, Yasuda J, Davis RJ. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 1998; 281: 1671-1674.
29. Nihalani D, Meyer D, Pajni S, Holzman LB. Mixed lineage kinase-dependent JNK activation is governed by interactions of scaffold protein JIP with MAPK module components. EMBO J 2001; 200: 3447-3458.
30. Hibi M, Lin A, Minden A, Karin M. Identification of an oncoprotein and UV-responsive protein kinase that binds and protentiates the c-Jun activation domain. Genes Dev 1993; 7: 2135-2148.
31. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK) - from inflammation to development. Curr Opin Cell Biol 1998; 10: 205-219.
32. Morton S, Davis R, McLaren A, Cohen P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 2003; 22: 3876-3886.
33. Le S, Connors TJ, Maroney AC. c-Jun N-terminal kinase specifically phosphorylates p66ShcA at serine 36 in response to ultraviolet irradiation. J Biol Chem 2001; 276: 48332-48336.
34. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432-2437.
35. Lin A. Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 2003; 25: 17-24.
36. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 36-42.
37. Lee CG, Cho SJ, Kang MJ, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor β1-induced pulmonary fibrosis. J Exp Med 2004; 200: 377-389.
38. Peffus L, Ma V, Tempest P, et al. Novel benzoxazepinone inhibitors of c-Jun N-terminal kinase 3 (JNK3) and utility as stroke therapeutics: - SAR and ligand co-crystallization studies. Abstr Pap Am Chem Soc 2005; 227: U12-U13.
39. Borsello T, Clarke P, Hirt L, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003; 9: 1180-1186.
40. Uehara T, Xi Peng X, Bennett B, et al. c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation 2004; 78: 324-332.
41. Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999; 6: 671-678.
42. Dickens M, Rogers J, Cavanagh J, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997; 277: 693-696.
43. Bennett BL, Satoh Y. JNK as a therapeutic target. In: Lin A, ed. The JNK Signaling Pathway. Georgetown, TX, Landes Bioscience, 2006; pp. 83-93.
44. Bain J, McLauchlan H, Elliot M, Cohen P. The specificities of protein kinase inhibitors: an update. Bioch J 2003; 371: 199-204.
45. Eynott PR, Xu L, Bennett BL, et al. Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats. Immunology 2004; 112: 446-453.
46. Eynott PR, Nath P, Leung SY, Adcock IM, Bennett BL, Chung KF. Allergen-induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N-terminal kinase. Br J Pharmacol 2003; 140: 1373-1380.
47. 2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. Eur J Pharmacol 2005; 506: 273-283.
48. Blease K, Leisten JC, Pai S, Groessel T, Shirley M, Raymon H. The small molecule JNK inhibitor, SP600125, attenuates bleomycin-induced pulmonary fibrosis. Inflamm Res 2003; 52: S153.
49. 2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther 2004; 310: 25-32.
50. Potier V, Julliard P, Camps M, et al. Efficacy of a novel inhibitor in reducing lung fibrosis. Inflamm Res 2003; 52: 27.
51. Henderson W Jr, Kain S, Teo J, Nguyen C, Kahn M. A small molecule inhibitor of redox-regulated NF-κB and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J Immunol 2002; 169:5294-5299.
52. Chen C-Y, Gherzi R, Andersen JS, et al. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev 2000; 14: 1236-1248.
53. Ming XF, Kaiser M, Moroni C. c-Jun N-terminal kinase is involved in AUUUA-mediated interleukin-3 mRNA turnover in mast cells. EMBO J 1998; 17: 6039-6048.
54. Dong C, Yang DD, Tournier C, et al. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000; 405: 91-94.
55. Nakahara T, Moroi Y, Uchi H, Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 2005; 42: 1-11.
56. Yao J, Mackman N, Edgington T, Fan S. Lipopolysaccharide induction of the tumor necrosis factor-α promoter in human monocytic cells. J Biol Chem 1997; 272: 17795-17801.
57. Kassel O, Sancono A, Kratzschmar J, Kreft B, Stassen M, Cato A. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 2001; 20: 7108-7116.
58. Adcock I, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79: 376-384.
59. Bruna A, Nicolas M, Munoz A, Kyriakis J, Caelles C. Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J 2003; 22: 6035-6044.
60. Sousa A, Lane S, Soh C, Lee T. In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. J Allergy Clin Immunol 1999; 104: 565-574.
61. Bantel H, Schmitz M, Raible A, Gregor M, Schulze-Osthoff K. Critical role of NF-κB and stress-activated protein kinases in steroid unresponsiveness. FASEB J 2002; 16: 1832-1834.
62. Hirst S, Hallsworth M, Peng Q, Lee T. Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1β and is mediated by the interleukin-4 receptor α-chain. Am J Respir Crit Care Med 2002; 165: 1161-1171.
63. Oltmanns U, Issa R, Sukkar M, John M, Chung KF. Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol 2003; 139: 1228-1234.
64. Kavurma M, Khachigan L. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 2003; 89: 289-300.
65. Zhai W, Eynott PR, Oltmanns U, Leung SY, Chung KF. Mitogen-activated protein kinase signalling pathways in IL-1β-dependent rat airway smooth muscle proliferation. Br J Pharmacol 2004; 143: 1042-1049.
66. Maki Y, Bos TJ, Davis C, Starbuck M, Vogt PK. Avian sarcoma virus 17 carries the jun oncogene. Proc Natl Acad Sci USA 1987; 84: 2848-2852.
67. 2-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 2002; 62: 1343-1348.
68. Westwick J, Lambert Q, Pestell R, et al. Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol 1997; 17: 1324-1335.
69. Potapova O, Gorospe M, Dougherty R, Dean N, Gaarde W, Holbrook N. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 2000; 20: 1713-1722.
70. Westwick J, Weitzel C, Leffert H, Brenner D. Activation of Jun kinase is an early event in hepatic regeneration. J Clin Invest 1995; 95: 803-810.
71. Schwabe RF, Bradham CA, Uehara T, et al. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 2003; 37: 824-832.
72. Jacobs-Helber SM, Sawyer ST. Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines. Blood 2004; 104: 696-703.
73. Pontrelli P, Ranieri E, Ursi M, et al. jun-N-terminal kinase regulates thrombin-induced PAI-1 gene expression in proximal tubular epithelial cells. Kidney Int 2004; 65: 2249-2261.
74. Ronai Z. JNKing revealed. Mol Cell 2004; 15: 843-844.
75. Hashimoto S, Gon Y, Takeshita K, Maruoka S, Horie T. IL-4 and IL-13 induce myofibroblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol 2001; 107: 1001-1008.
76. Lee V, Schroedl C, Brunelle J, et al. Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway. Am J Physiol 2005; 289: L521-L528.
77. Blanc R, Ma F, Tesch G, et al. JNK blockade reduces renal fibrosis in unilateral ureteric obstruction. J Am Soc Nephrol 2005; 16: 609A.
78. Javelaud D, Laboureau J, Gabison E, Verrecchia F, Mauviel A. Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J Biol Chem 2003; 278: 24624-24628.
79. Hocevar B, Brown T, Howe P. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999; 18: 1345-1356.
80. 2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-β1 in human lung fibroblasts. Am J Respir Cell Mol Biol 2003; 28: 754-761.
81. Ventura J, Kennedy N, Flavell R, Davis R. JNK regulates autocrine expression of TGF-β1. Mol Cell 2004; 15: 269-278.
82. Lee KY, Ito K, Hayashi K, Jazrawi EP, Barnes PJ, Adcock IM. NF-κB and activator protein 1 response elements and the role of histone modifications in IL-1β-induced TGF-β1 gene transcription. J Immunol 2006; 176: 603-615.
83. Ning W, Li C, Kaminski N, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004; 101: 14895-14900.
84. Lim CP, Jain N, Cao X. Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1. Oncogene 1998; 16: 2915-2926.
85. Yu C, Minemoto Y, Zhang J, et al. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004; 13: 329-340.
86. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776.
87. Kuo W, Chen J, Lin H, Chen B, Hsu J, Wang C. Induction of apoptosis in the lung tissue from rats exposed to cigarette smoke involves p38/JNK MAPK pathway. Chem Biol Interact 2005; 155: 31-42.
88. Buccellato LJ, Tso M, Akinci OI, Chandel NS, Budinger GR. Reactive oxygen species are required for hyperoxia-induced Bax activation and cell death in alveolar epithelial cells. J Biol Chem 2004; 279: 6753-6760.
89. Bradham C, Stachlewitz RF, Gao W, et al. Reperfusion after liver transplantation in rats differentially activates the mitogen-activated protein kinases. Hepatology 1997; 25: 1128-1135.
90. 2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs. J Immunol 2004; 172: 2569-2577.
91. Li Y, Arita Y, Koo H, Davis J, Kazzaz J. Inhibition of c-Jun N-terminal kinase pathway improves cell viability in response to oxidant injury. Am J Respir Cell Mol Biol 2003; 29: 779-783.
92. Levi-Schaffer F, Temkin V, Malamud V, Feld S, Zilberman Y. Mast cells enhance eosinophil survival in vitro: role of TNF-α and granulocyte-macrophage colony-stimulating factor. J Immunol 1998; 160: 5554-5562.
93. Gardai S, Hoontrakoon R, Goddard C, et al. Oxidant-mediated mitochondrial injury in eosinophil apoptosis: enhancement by glucocorticoids and inhibition by granulocyte-macrophage colony-stimulating factor. J Immunol 2003; 170: 556-566.
94. Zhang X, Moilanen E, Lahti A, et al. Regulation of eosinophil apoptosis by nitric oxide: role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5. J Clin Immunol 2003; 112: 93-101.
95. Teramoto H, Salem P, Robbins K, Bustelo X, Gutkind JS. Tyrosine phosphorylation of the vav proto-oncogene product links Fc?RI to the Rac1-JNK pathway. J Biol Chem 1997; 272: 10751-10755.
96. Garrington T, Ishizuka T, Papst P, et al. MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. EMBO J 2000; 19: 5387-5395.
97. Cloutier A, Ear T, Borissevitch O, Larivee P, McDonald PP. Inflammatory cytokine expression is independent of the c-Jun N-terminal kinase/AP-1 signaling cascade in human neutrophils. J Immunol 2003; 171: 3751-3761.